---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-041569"
form_type: "8-K/A"
ticker: "ASRT"
cik: "0001808665"
company_name: "Assertio Holdings, Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:48:33.944645+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Assertio to be acquired by Garda Therapeutics in $18.00/share cash tender offer plus CVRs

## Summary
- Acquisition by Garda Therapeutics at $18.00/share cash plus one CVR per share; tender offer to commence within 10 business days.
- Asset sale to Cosette Pharmaceuticals for $35M cash upfront plus up to $32M in milestone payments and SPRIX-related CVR payments.
- Equity commitment of $17M from Joseph Limber and Brett Lund; debt commitment of $87M from Colbeck Capital Management.
- Termination fee: $4.8M standard, reduced to $1.75M for a Qualified Bidder prior to Window Shop End Time.
- CEO Mark Reisenauer's non-compete extended to 18 months post-termination in connection with the merger.

## SEC filing metadata
- accession: 0001104659-26-041569
- form_type: 8-K/A
- ticker: ASRT
- cik: 0001808665
- company_name: Assertio Holdings, Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808665/000110465926041569/0001104659-26-041569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808665/000110465926041569/tm2611405d4_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-041569
- JSON: https://secwatch.observer/filing/0001104659-26-041569.json
- Plain text: https://secwatch.observer/filing/0001104659-26-041569.txt

## Source-grounded claims
- claim_id: 27289305d0321bcd2954c50987d9b8acec3d36e8
  claim: Assertio Holdings, Inc. entered into Agreement and Plan of Merger with Garda Therapeutics, Inc. valued at $18.00 per share of Common Stock in cash, plus one contingent value right per share (effective 2026-04-08).
  evidence_excerpt: On April 8, 2026, Assertio Holdings, Inc. (the " Company " or " Assertio ") entered into an Agreement and Plan of Merger (the " Merger Agreement ") with Garda Therapeutics, Inc., a Delaware corporation (" Parent "), and Audi Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (" Purchaser ").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808665/000110465926041569/0001104659-26-041569-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.